Anti‐TNF dose reduction vs anti‐TNF continuation: Maintenance of clinical remission
Anti‐TNF dose reduction showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐TNF dose reduction vs anti‐TNF continuation Proportion of participants with persistent remission · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents Anti‐TNF dose reduction showed no clear difference in proportion of participants with persistent remission compared with anti‐TNF continuation (low certainty). Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid… (2019) · Cochrane Headline outcomes only | RR 1.01 [0.8, 1.28] | 2 studies · 612 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low… 2019 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.